- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00653276
MD Ezetimibe Cyclosporine Interaction (0653-057)
February 7, 2022 updated by: Organon and Co
An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects
Study to determine the effect of multiple oral doses of ezetimibe on the pharmacokinetics of a single oral dose cyclosporine in young healthy males and females.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is male or female between 18 to 45 years of age
- Subject is judged to be in good health on the basis of history, physical examination, and routine laboratory data
Exclusion Criteria:
- Premenopausal women who are currently pregnant or who are currently nursing
- Subjects with drug or substance abuse, poor mental function, history of major gastrointestinal abnormalities (stomach issues), or high cholesterol
- Subject that has donated blood or has participated in another clinical trial within the last four weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment A
Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
|
single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
|
Active Comparator: Treatment B
Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
|
single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety and tolerability of cyclosporine coadministered with ezetimibe vs. cyclosporine administered alone.
Time Frame: Blood sampling will be conducted for 48 hours starting with the first cyclosporine dosing.
|
Blood sampling will be conducted for 48 hours starting with the first cyclosporine dosing.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2003
Primary Completion (Actual)
January 1, 2004
Study Completion (Actual)
January 1, 2004
Study Registration Dates
First Submitted
April 1, 2008
First Submitted That Met QC Criteria
April 1, 2008
First Posted (Estimate)
April 4, 2008
Study Record Updates
Last Update Posted (Actual)
February 18, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
- Ezetimibe
Other Study ID Numbers
- 0653-057
- MK0653-057
- 2008_520
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholesterol
-
Texas A&M UniversityCompletedCholesterol, LDL | Cholesterol, HDL | Research SubjectsUnited States
-
Universidad Católica San Antonio de MurciaCompleted
-
Organon and CoSchering-PloughCompleted
-
Arizona State UniversityNorth American Millers Association - Corn DivisionCompletedGut Microbiome | Cholesterol, LDL | Cholesterol, HDLUnited States
-
Universidad de GranadaUniversity of Copenhagen; University of Oxford; Harvard University; University... and other collaboratorsRecruiting
-
Uppsala UniversityDalarna County Council, SwedenCompleted
-
University of California, Los AngelesWithdrawnCholesterol LoweringUnited States
-
Supplement Formulators, Inc.CompletedA Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol LevelsCholesterol HealthUnited States
-
Yonsei UniversityCompleted
-
Unity Health TorontoUnknown
Clinical Trials on Comparator: cyclosporine
-
Zynerba Pharmaceuticals, Inc.CompletedFragile X SyndromeUnited States, New Zealand, Australia
-
Université Catholique de LouvainRecruiting
-
AllerganCompletedDry Eye SyndromesUnited States
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCTerminated
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Merck Sharp & Dohme LLCTerminatedType 2 Diabetes
-
Cognition TherapeuticsRecruitingAge-Related Macular DegenerationUnited States
-
Merck Sharp & Dohme LLCCompleted